Abstract
Pulmonary arterial hypertension (HAP) is a clinical, chronic and progressive condition that affects the pulmonary vasculature. It is characterized by the presence of pre-implanted pulmonary hypertension (HP), in the absence of other causes such as HP secondary to pulmonary disease or HP chronic thromboembolic disease, and by vascular resistance. The progressive increase in pressure And of the resistance can lead to right heart failure and, finally, to the premature death of the patient.
Keywords
Pulmonary arterial hypertension; Lung diseases; Selexipag
Bibliographic citation
Selexipag per al tractament de la hipertensió arterial pulmonar. Barcelona: Servei Català de la Salut; 2017.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/3530This item appears in following collections
The following license files are associated with this item: